Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Link Between Specific Antibodies And Spina Bifida Ruled Out By Irish-Led Research Team
New research, publishedin the New England Journal of Medicine, shows that a woman"s risk of having a child with a neural tube defect (NTD), such as Spina Bifida, is not linked to folic acid related auto-antibodies. The findings refute a well publicised study in 2004, which had indicated a link between the presence of these auto-antibodies in the circulation of mothers who had children with Spina Bifida compared to those who did not.

ATS Medical Announces FDA Clearance And First Implant Of New ATS Simulus Semi-Rigid Annuloplasty Band
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced FDA clearance and the first implant of the ATS Simulus(R) Semi-Rigid Annuloplasty Band. The Simulus Semi-Rigid Annuloplasty Band was developed through the Company"s collaboration with Genesee BioMedical and represents the latest addition to the expanding portfolio of valve repair products.
News of the day
Positive CHMP Opinion For JAVLOR(R) In Metastatic Treatment Of Bladder Cancer After Failure Of A Prior Platinum-Containing Regimen
Laboratoires Pierre Fabre announce that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen).
Nutrition

Myeloid Proteins Reflect Disease Activity And Treatment Response In Familial Mediterranean Fever

Serum levels of the pro-inflammatory biomarkers myeloid-related protein (MRP) 8 and 14 are increased to a greater extent in patients with Familial Mediterranean Fever (FMF) during flare than in patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID) or patients with Muckle Wells Syndrome (MWS), according to the results of a new study presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark. Results of the study indicate that measurement of levels of these biomarkers may enable the prediction of: disease activity, response to anti-inflammatory treatment, differentiation of disorders leading to Fever of Unknown Origin and, potentially, detection of subclinical inflammatory activity in children and adolescents with FMF. Dr Helmut Wittkowski of the University Hospital Muenster, Germany, who led the study said: "The identification of the role of MRP8/14 during high inflammatory episodes, as well as during successful therapy, offers new insight into the complex underlying mechanisms involved in FMF. Tracking levels of MRP 8/14 may prove a marker for disease activity in FMF and may even lead to earlier diagnosis and improved treatment options for this unique patient population." MRP8/14 are endogenous danger-signals (damage-associated molecular pattern (DAMP) molecules) that play an important role in inflammatory and immunological responses. They have recently been identified as activators of toll like receptor 4 (TLR-4), a molecule that amplifies phagocyte activation (a type of white blood cell, leucocyte), supporting the immune system by neutralising or engulfing bacteria or other invading micro-organisms. The mean serum levels of MRP8/14 in inflammatory episodes of FMF (343.210÷±202.210 ng/ml) were found to be significantly higher than in NOMID (2.830÷±580 ng/ml; p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009